Elucidating the exact pharmacological system of action (MOA) of naturally developing compounds may be tough. While Tarselli et al. (sixty) designed the first de novo artificial pathway to conolidine and showcased this Obviously happening compound successfully suppresses responses to both of those chemically induced and inflammation-derived soreness